Home / OKUR : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does OKUR make money? Does OKUR have pricing power? What's the Earnings Whisper? Will OKUR profit more as the business scales? What is OKUR's management track record? Is OKUR's current price justified?

OnKure Therapeutics, Inc.

$2.98 +$0.02 (+0.84%)

NASDAQ · 14 Sep 2026 15:18 UTC

Previous Close

$3.1

Day Range

$2.98$3.14

Year Range

$2.23$5.38

Market Cap

120.88M

AVG Volume

256.85K

Trailing/Forward PE

-0.85/-

PEG ratio

0.05

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

NASDAQ

Net Income (USD)

OKUR Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-15.35M
26 Q1	-15.16M
25 Q4	-13.5M
25 Q3	-14.7M
25 Q2	-15.39M
25 Q1	-15.93M
24 Q4	-35.19M
24 Q3	-3.69M
24 Q2	-14.14M
24 Q1	-9.54M

Operating Income (USD)

OKUR Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-16.9M
26 Q1	-15.62M
25 Q4	-14.12M
25 Q3	-15.5M
25 Q2	-16.32M
25 Q1	-17M
24 Q4	-33.8M
24 Q3	-4.67M
24 Q2	-14.34M
24 Q1	-9.83M

EBITDA (USD)

OKUR EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-15.35M
26 Q1	-14.95M
25 Q4	-13.29M
25 Q3	-14.49M
25 Q2	-15.18M
25 Q1	-15.71M
24 Q4	-31.16M
24 Q3	-3.68M
24 Q2	-13.96M
24 Q1	-9.38M

Cash Flows (USD)

OKUR Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-10.36M
26 Q1	-12.94M
25 Q4	-11.52M
25 Q3	-13.04M
25 Q2	-13.29M
25 Q1	-14.02M
24 Q4	-21.07M
24 Q3	-10.68M
24 Q2	-6.48M
24 Q1	-10.64M

EPS (USD)

OKUR EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.31
26 Q1	-1.11
25 Q4	-0.99
25 Q3	-1.09
25 Q2	-1.14
25 Q1	-1.19
24 Q4	-2.64
24 Q3	-0.28
24 Q2	-1.06
24 Q1	-0.71

Expenses (USD)

OKUR Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	16.9M
26 Q1	15.62M
25 Q4	14.13M
25 Q3	15.51M
25 Q2	16.34M
25 Q1	17.02M
24 Q4	33.84M
24 Q3	4.68M
24 Q2	14.35M
24 Q1	9.84M

Cash & Debt (USD)

OKUR Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	176.39M
26 Q1	192.11M
25 Q4	59.05M
25 Q3	70.33M
25 Q2	83.37M
25 Q1	96.66M
24 Q4	110.76M
24 Q3	76.67M
24 Q2	18.63M
24 Q1	19.25M

Debt ratios

OKUR Debt ratios by quarter
Period	Debt ratios
26 Q2	3.02
26 Q1	3.31
25 Q4	1
25 Q3	0.91
25 Q2	1.26
25 Q1	1.48
24 Q4	1.88
24 Q3	9.41
24 Q2	0.52
24 Q1	1.06

Return on Capital

OKUR Return on Capital by quarter
Period	Return on Capital
26 Q2	-8.92%
26 Q1	-8.22%
25 Q4	-24.03%
25 Q3	-22.13%
25 Q2	-19.69%
25 Q1	-17.57%
24 Q4	-33.9%
24 Q3	-4.99%
24 Q2	11.44%
24 Q1	8.57%

Shares Outstanding

OKUR Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	49.87M
26 Q1	13.67M
25 Q4	13.52M
25 Q3	13.51M
25 Q2	13.51M
25 Q1	13.42M
24 Q4	13.34M
24 Q3	13.34M
24 Q2	13.34M
24 Q1	13.34M

Book Value Per Share (USD)

OKUR Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	3.45
26 Q1	13.48
25 Q4	4.16
25 Q3	4.92
25 Q2	5.79
25 Q1	6.75
24 Q4	7.78
24 Q3	5.55
24 Q2	-9.26
24 Q1	-8.34

Total Assets (USD)

OKUR Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	179.35M
26 Q1	198.69M
25 Q4	62.12M
25 Q3	72.83M
25 Q2	86.07M
25 Q1	99.88M
24 Q4	114.91M
24 Q3	77.64M
24 Q2	25.47M
24 Q1	24.53M

Employee Count

OKUR Employee Count by quarter
Period	Employee Count
2025	45
2024	46
2023	8
2022	36
2021	20

Free Cash Flow Yield

OKUR Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-30.96%
Sep 26	-26.81%
Aug 26	-25.32%
Aug 26	-24.36%
Aug 26	-24.05%
Aug 26	-23.18%
Jul 26	-97.24%
Jul 26	-90.16%
Jul 26	-88.44%
Jul 26	-86.79%
Jul 26	-81.1%
Jun 26	-82.54%
Jun 26	-82.91%
Jun 26	-88.44%
Jun 26	-88.65%
May 26	-88.44%
May 26	-88.23%
May 26	-117.55%
May 26	-95%
May 26	-81.14%
Apr 26	-79.96%
Apr 26	-76.76%
Apr 26	-89.26%
Apr 26	-89.46%
Mar 26	-96.19%
Mar 26	-91.6%
Mar 26	-101.53%
Mar 26	-149.06%
Feb 26	-167.76%
Feb 26	-174.86%
Feb 26	-187.87%
Feb 26	-181.86%
Jan 26	-172.21%
Jan 26	-155.17%
Jan 26	-151.55%
Jan 26	-144.79%
Jan 26	-153.6%
Dec 25	-162.37%
Dec 25	-151.04%
Dec 25	-148.09%
Dec 25	-148.58%
Nov 25	-151.04%
Nov 25	-176.22%
Nov 25	-145.25%
Nov 25	-154.64%
Oct 25	-128.95%
Oct 25	-131.67%
Oct 25	-157.25%
Oct 25	-143.33%
Oct 25	-161.31%
Sep 25	-174.16%
Sep 25	-170.09%
Sep 25	-178.43%
Sep 25	-158.96%
Aug 25	-158.96%
Aug 25	-154.47%
Aug 25	-172.78%
Aug 25	-190.79%
Aug 25	-176.92%
Jul 25	-168.49%
Jul 25	-167.05%
Jul 25	-155.69%
Jul 25	-163.54%
Jun 25	-162.17%
Jun 25	-164.23%
Jun 25	-146.87%
Jun 25	-135.15%
May 25	-153.84%
May 25	-181.03%
May 25	-194.61%
May 25	-202.72%
May 25	-146.53%
Apr 25	-140.89%
Apr 25	-126.75%
Apr 25	-124.18%
Apr 25	-117.04%
Mar 25	-82.13%
Mar 25	-72.54%
Mar 25	-79.46%
Mar 25	-72.97%
Feb 25	-27.31%
Feb 25	-25.36%
Feb 25	-24.12%
Feb 25	-23.66%
Jan 25	-22.51%
Jan 25	-24.46%
Jan 25	-23.91%
Jan 25	-18.63%
Jan 25	-15.43%
Dec 24	-16.97%
Dec 24	-16.52%
Dec 24	-14.04%
Dec 24	-9.78%
Nov 24	-8.98%
Nov 24	-12.81%
Nov 24	-12%
Nov 24	-11.33%
Nov 24	-12.23%
Oct 24	-11.7%
Oct 24	-10.76%

Price to Book

OKUR Price to Book by quarter
Period	Price to Book
Sep 26	0.9
Sep 26	1.04
Aug 26	1.1
Aug 26	1.14
Aug 26	1.16
Aug 26	1.2
Jul 26	0.28
Jul 26	0.31
Jul 26	0.31
Jul 26	0.32
Jul 26	0.34
Jun 26	0.33
Jun 26	0.33
Jun 26	0.31
Jun 26	0.31
May 26	0.31
May 26	0.31
May 26	0.23
May 26	0.29
May 26	1.14
Apr 26	1.15
Apr 26	1.2
Apr 26	1.03
Apr 26	1.03
Mar 26	0.96
Mar 26	1.01
Mar 26	0.91
Mar 26	0.62
Feb 26	0.55
Feb 26	0.53
Feb 26	0.49
Feb 26	0.51
Jan 26	0.54
Jan 26	0.6
Jan 26	0.61
Jan 26	0.64
Jan 26	0.6
Dec 25	0.57
Dec 25	0.61
Dec 25	0.62
Dec 25	0.62
Nov 25	0.61
Nov 25	0.52
Nov 25	0.64
Nov 25	0.6
Oct 25	0.59
Oct 25	0.57
Oct 25	0.48
Oct 25	0.53
Oct 25	0.47
Sep 25	0.43
Sep 25	0.44
Sep 25	0.42
Sep 25	0.48
Aug 25	0.48
Aug 25	0.49
Aug 25	0.44
Aug 25	0.3
Aug 25	0.33
Jul 25	0.34
Jul 25	0.35
Jul 25	0.37
Jul 25	0.35
Jun 25	0.36
Jun 25	0.35
Jun 25	0.39
Jun 25	0.43
May 25	0.37
May 25	0.32
May 25	0.3
May 25	0.28
May 25	0.32
Apr 25	0.33
Apr 25	0.37
Apr 25	0.38
Apr 25	0.4
Mar 25	0.57
Mar 25	0.65
Mar 25	0.59
Mar 25	0.64
Feb 25	0.91
Feb 25	0.98
Feb 25	1.03
Feb 25	1.05
Jan 25	1.11
Jan 25	1.02
Jan 25	1.04
Jan 25	1.34
Jan 25	1.62
Dec 24	1.47
Dec 24	1.51
Dec 24	1.78
Dec 24	2.55
Nov 24	2.78
Feb 24	1.87
Feb 24	1.91
Feb 24	2.02
Feb 24	1.85
Jan 24	1.91
Jan 24	1.87

No video analysis for this stock yet. Request one from our team.

News: OKUR

globenewswire.com · 31 Aug 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.

globenewswire.com · 4 Aug 2026

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027

marketbeat.com · 15 Jul 2026

OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near

OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.

globenewswire.com · 2 Jul 2026

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company's structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, click here.